Table 5 Comparison of final pathological carcinoma risks based on endometrial sampling methods
From: Aspiration biopsy versus dilatation and curettage for endometrial hyperplasia prior to hysterectomy
Endometrial sampling pathology | Carcinoma on final pathology | Endometrial sampling method | P | |
|---|---|---|---|---|
D&C (n = 100) | Aspiration biopsy (n = 150) | |||
Hyperplasia without atypia | No | 55 (98.2) | 58 (93.5) | 0.368* |
Yes | 1 (1.8) | 4 (6.5) | ||
Atypical hyperplasia | No | 30 (68.2) | 51 (58.0) | 0.255 |
Yes | 14 (31.8) | 37 (42.0) | ||
Total | No | 85 (85.0) | 109 (72.7) | 0.022 |
Yes | 15 (15.0) | 41 (27.3) | ||